-

12:04:16 AM

GNPX Stock News

GNPX - Genprex Inc

01/10/22 9:17 AM

Nasdaq : GNPX

clinical trial

Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a plan to accelerate the opening of clinical trial sites for the Acclaim-1 clinical trial which combines the Company’ s lead product candidate, REQORSA™ Immunogene Therapy with AstraZeneca’ s Tagrisso ®,...

RHEA-AI

very positive

01/05/22 8:00 AM

Nasdaq : GNPX

conferences

Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its participation in upcoming investor and healthcare conferences to be held in January 2022. Event: HC Wainwright BIOCONNECT 2022 Virtual Conference Conference Dates: January 10-13, 2022...

RHEA-AI

neutral

01/04/22 8:00 AM

Nasdaq : GNPX

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has expanded its oncology research and development pipeline to include small cell lung cancer as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy.

RHEA-AI

neutral

01/03/22 8:00 AM

Nasdaq : GNPX

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the Company’ s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck& Co’ s Keytruda ® in patients with...

RHEA-AI

very positive

11/16/21 8:30 AM

Nasdaq : GNPX

conferences

Genprex to Present in November CEO Roadshow Webinar

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be presenting in November with CEO Roadshow to provide a company overview of its novel gene therapies in cancer and diabetes to...

RHEA-AI

neutral

09/28/21 6:50 AM

Nasdaq : GNPX

Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the...

RHEA-AI

very positive

09/20/21 7:00 AM

Nasdaq : GNPX

conferences

Genprex to Participate in September Investor Conferences

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in two investor conferences in September 2021. Benzinga Healthcare Small Cap Conference. Genprex, Inc. is a...

RHEA-AI

neutral

07/20/21 8:30 AM

Nasdaq : GNPX

conferences

Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will be participating in a webinar

RHEA-AI

neutral

06/23/21 8:30 AM

Nasdaq : GNPX

clinical trial

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been

RHEA-AI

neutral

05/19/21 8:30 AM

Nasdaq : GNPX

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that it will participate in Noble Capital Markets’ Virtual Roadshow Series, presented by Channelchek on May

RHEA-AI

neutral

GNPX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.genprex.com
CeoJ. Rodney Varner
Security nameGenprex Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1601 Trinity St Bldg B
StateTexas
CityAustin
Zip78712-1765
CountryUS
Phone15125377997

GNPX Description:

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.